Optimizing management of chronic obstructive pulmonary disease in the upcoming decade

Richard Russell, Antonio R Anzueto, Idelle Weisman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and mortality. Caring for patients with COPD, particularly those with advanced disease who experience frequent exacerbations, places a significant burden on health care budgets, and there is a global need to reduce the financial and personal burden of COPD. Evolving scientific evidence on the natural history and clinical course of COPD has fuelled a fundamental shift in our approach to the disease. The emergence of data highlighting the heterogeneity in rate of lung function decline has altered our perception of disease progression in COPD and our understanding of appropriate strategies for the management of stable disease. These data have demonstrated that early, effective, and prolonged bronchodilation has the potential to slow the rate of decline in lung function and to reduce the frequency of exacerbations that contribute to functional decline. The goals of therapy for COPD are no longer confined to controlling symptoms, reducing exacerbations, and maintaining quality of life, and slowing disease progression is now becoming an achievable aim. A challenge for the future will be to capitalize on these observations by improving the identification and diagnosis of patients with COPD early in the course of their disease, so that effective interventions can be introduced before the more advanced, disabling, and costly stages of the disease. Here we critically review emerging data that underpin the advances in our understanding of the clinical course and management of COPD, and evaluate both current and emerging pharmacologic options for effective maintenance treatment.

Original languageEnglish (US)
Pages (from-to)47-61
Number of pages15
JournalInternational Journal of COPD
Volume6
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Chronic Obstructive Pulmonary Disease
Disease Progression
Lung
Budgets
Disease Management
Natural History
Quality of Life
Delivery of Health Care
Mortality
Therapeutics

Keywords

  • Chronic obstructive pulmonary disease
  • COPD
  • Early treatment
  • Long-acting bronchodilator

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health
  • Health Policy

Cite this

Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. / Russell, Richard; Anzueto, Antonio R; Weisman, Idelle.

In: International Journal of COPD, Vol. 6, No. 1, 2011, p. 47-61.

Research output: Contribution to journalArticle

@article{bf1c4fdc21ce445189679664cd50f376,
title = "Optimizing management of chronic obstructive pulmonary disease in the upcoming decade",
abstract = "Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and mortality. Caring for patients with COPD, particularly those with advanced disease who experience frequent exacerbations, places a significant burden on health care budgets, and there is a global need to reduce the financial and personal burden of COPD. Evolving scientific evidence on the natural history and clinical course of COPD has fuelled a fundamental shift in our approach to the disease. The emergence of data highlighting the heterogeneity in rate of lung function decline has altered our perception of disease progression in COPD and our understanding of appropriate strategies for the management of stable disease. These data have demonstrated that early, effective, and prolonged bronchodilation has the potential to slow the rate of decline in lung function and to reduce the frequency of exacerbations that contribute to functional decline. The goals of therapy for COPD are no longer confined to controlling symptoms, reducing exacerbations, and maintaining quality of life, and slowing disease progression is now becoming an achievable aim. A challenge for the future will be to capitalize on these observations by improving the identification and diagnosis of patients with COPD early in the course of their disease, so that effective interventions can be introduced before the more advanced, disabling, and costly stages of the disease. Here we critically review emerging data that underpin the advances in our understanding of the clinical course and management of COPD, and evaluate both current and emerging pharmacologic options for effective maintenance treatment.",
keywords = "Chronic obstructive pulmonary disease, COPD, Early treatment, Long-acting bronchodilator",
author = "Richard Russell and Anzueto, {Antonio R} and Idelle Weisman",
year = "2011",
doi = "10.2147/COPD.S13758",
language = "English (US)",
volume = "6",
pages = "47--61",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Optimizing management of chronic obstructive pulmonary disease in the upcoming decade

AU - Russell, Richard

AU - Anzueto, Antonio R

AU - Weisman, Idelle

PY - 2011

Y1 - 2011

N2 - Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and mortality. Caring for patients with COPD, particularly those with advanced disease who experience frequent exacerbations, places a significant burden on health care budgets, and there is a global need to reduce the financial and personal burden of COPD. Evolving scientific evidence on the natural history and clinical course of COPD has fuelled a fundamental shift in our approach to the disease. The emergence of data highlighting the heterogeneity in rate of lung function decline has altered our perception of disease progression in COPD and our understanding of appropriate strategies for the management of stable disease. These data have demonstrated that early, effective, and prolonged bronchodilation has the potential to slow the rate of decline in lung function and to reduce the frequency of exacerbations that contribute to functional decline. The goals of therapy for COPD are no longer confined to controlling symptoms, reducing exacerbations, and maintaining quality of life, and slowing disease progression is now becoming an achievable aim. A challenge for the future will be to capitalize on these observations by improving the identification and diagnosis of patients with COPD early in the course of their disease, so that effective interventions can be introduced before the more advanced, disabling, and costly stages of the disease. Here we critically review emerging data that underpin the advances in our understanding of the clinical course and management of COPD, and evaluate both current and emerging pharmacologic options for effective maintenance treatment.

AB - Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and mortality. Caring for patients with COPD, particularly those with advanced disease who experience frequent exacerbations, places a significant burden on health care budgets, and there is a global need to reduce the financial and personal burden of COPD. Evolving scientific evidence on the natural history and clinical course of COPD has fuelled a fundamental shift in our approach to the disease. The emergence of data highlighting the heterogeneity in rate of lung function decline has altered our perception of disease progression in COPD and our understanding of appropriate strategies for the management of stable disease. These data have demonstrated that early, effective, and prolonged bronchodilation has the potential to slow the rate of decline in lung function and to reduce the frequency of exacerbations that contribute to functional decline. The goals of therapy for COPD are no longer confined to controlling symptoms, reducing exacerbations, and maintaining quality of life, and slowing disease progression is now becoming an achievable aim. A challenge for the future will be to capitalize on these observations by improving the identification and diagnosis of patients with COPD early in the course of their disease, so that effective interventions can be introduced before the more advanced, disabling, and costly stages of the disease. Here we critically review emerging data that underpin the advances in our understanding of the clinical course and management of COPD, and evaluate both current and emerging pharmacologic options for effective maintenance treatment.

KW - Chronic obstructive pulmonary disease

KW - COPD

KW - Early treatment

KW - Long-acting bronchodilator

UR - http://www.scopus.com/inward/record.url?scp=79251468722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251468722&partnerID=8YFLogxK

U2 - 10.2147/COPD.S13758

DO - 10.2147/COPD.S13758

M3 - Article

C2 - 21311693

AN - SCOPUS:79251468722

VL - 6

SP - 47

EP - 61

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

IS - 1

ER -